Topics in Anti-Cancer Research

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Rahman, Atta-ur-, 1942-
Otros Autores: Zaman, Khurshid
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Sharjah : Bentham Science Publishers, 2018.
Temas:
Cancer > Prevention.
Cancer > Research.
Cancer > Treatment.
Tumors.
Neoplasms
Cancer > Prévention.
Cancer > Recherche.
Cancer > Traitement.
Tumeurs.
Cancer > Prevention
Cancer > Research
Cancer > Treatment
Tumors
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Cover; Title; Biblography; End User License Agreement; Contents; Preface; Introduction; List of Contributors; The Role of ncRNAs in Human Cancer and its Related Patents; María I. Navarro-Mendoza1, Carlos Pérez-Arques1, Laura Murcia1, Alfonso F. López-Martínez2 and Francisco E. Nicolás1,*; 1. INTRODUCTION; 2. SMALL NCRNAS: MIRNAS, PIRNAS, TIRNAS, SNORNAS AND PARNAS; 2.1. miRNAs; 2.2. piRNAs; 2.3. tiRNAs; 2.4. snoRNAs; 2.5. Small Promoter Associated RNAs; 2.6. Other Small ncRNAs; 3. LONG NCRNAS: LINCRNAS, T-UCRS, CERNAS AND OTHER LNCRNAS; 3.1. LincRNAs; 3.2. T-UCRs; 3.3. CeRNAs
  • 3.4. Other lncRNAsCURRENT & FUTURE DEVELOPMENTS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; DISCLOSURE; REFERENCES; Taxol To Nanotaxol: A Journey Towards Enhanced Drug Delivery; Tanvi Kaku1, Aiswarya Dash2 and Biswa P. Chatterji2,*; 1. INTRODUCTION; 1.1. Methods for Preparation of Paclitaxel Nanoparticles; 1.1.1. CN1463969A; 1.1.2. CN101829061A; 1.2. Human Serum Albumin (HSA) Associated and Other Protein Associated and Functionalized Taxol® or Paclitaxel Nanoparticles as Drug Delivery Agents; 1.2.1. US6506405B1; 1.2.2. US8268348B2 and US20100112077A1
  • 1.2.3. WO1994018954A11.2.4. US20040092577A1; 1.2.5. US20090004118; 1.2.6. US20090226393; 1.2.7. US20100015051; 1.2.8. US20100303723; 1.2.9. WO2007034479; 1.3. Micelles, Emulsions and Liposomes as Drug Delivery Carriers for Paclitaxel; 1.3.1. US20150366806; 1.3.2. WO2009070761; 1.3.3. EP2494956 and EP2494957; 1.3.4. WO1994007484; 1.3.5. WO1996002247; 1.3.6. CN102772368A; 1.3.7. US5424073; 1.3.8. KR101612194; 1.3.9. US8663599B1; 1.4. Carbon Nanoparticles as Drug Delivery Agents for Cancer Chemotherapy; 1.4.1. EP3063091; 1.4.2. US20090087493; 1.4.3. KR20180016231; 1.4.4. CN104998261
  • 1.4.5. WO20140153341.5. Nanodevices for Paclitaxel Delivery to Cancer Cells; 1.5.1. US20100215724; 1.5.2. US20100303716; DISCUSSION; CURRENT & FUTURE DEVELOPMENTS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Advanced Therapy in Cancer: Stimuli-Responsive Nanocarriers for On-Demand Drug Delivery; Azadeh Haeri*, Fatemeh Mehryab and Hamid R. Moghimi; 1. INTRODUCTION; 2. STIMULI-RESPONSIVE NANOCARRIERS; 3. EXTERNAL STIMULI-RESPONSIVE DRUG DELIVERY; 3.1. Temperature-Responsive Nanocarriers; 3.2. Magnetic Field-Responsive Nanocarriers
  • 3.3. Photo-Responsive Nanocarriers3.4. Ultrasound-Responsive Nanocarriers; 4. INTERNAL STIMULI-RESPONSIVE DRUG DELIVERY; 4.1. pH-Responsive Nanocarriers; 4.2. Enzyme-Responsive Nanocarriers; 4.3. Redox-Responsive Nanocarriers; 5. OTHER STIMULI-RESPONSIVE NANOCARRIERS; CONCLUSION; CURRENT & FUTURE DEVELOPMENTS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; The Regulation and the Function of Autophagy in the Development and Behavior of Esophageal Cancers; Erdem Ayik* and Gulsum O. Elpek; 1. INTRODUCTION; 2. GENERAL ASPECTS OF AUTOPHAGY; 3. AUTOPHAGY IN CANCER

Ejemplares similares